Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Lee S. Rosen, M.D.
Lee S. Rosen, M.D.

Specialty:

Hematology
Medical Oncology

General Information:

Gender:
Male
Language(s):
English, Hebrew, Spanish, French

Affiliation(s):

Visiting Professor, Department of Medicine, Hematology/Oncology
Co-Director, UCLA Santa Monica Hematology Oncology at 2020
Director, Phase I Drug Development Program
Member, JCCC Signal Transduction and Therapeutics Program Area

Hospital Affiliation(s):

Ronald Reagan UCLA Medical Center
UCLA Medical Center, Santa Monica

Education:

Fellowship:
Hematology/Oncology, UCLA School of Medicine, 1993 - 1996
Residency:
Internal Medicine, UCLA School of Medicine, 1991 - 1993
Internship:
Internal Medicine, UCLA School of Medicine, 1990 - 1991
Medical Degree:
M.D., Baylor College of Medicine, 1990
Degree:
M.P.P., Public Policy, Harvard University, JFK School of Government, 1986

Certification(s):

Medical Board Certification(s):
Medical Oncology, American Board of Internal Medicine, 2010
Hematology, American Board of Internal Medicine, 1998
Internal Medicine, American Board of Internal Medicine, 1993

Contact Information:

Phone:
(310) 633-8400
Email:

Practice Information:

Clinical Interest(s):
Advanced Malignancies
Cancers of Digestive Tract
Colorectal (colon, rectum and anus)
Esophageal Cancer
Gastric Cancer
Gastrointestinal Malignancies
General Oncology
Hepatobiliary Cancers
Liver Cancer
Pancreatic Cancer
Phase I Clinical Trials
Unknown Primary

Scientific Interest(s):

Dr. Lee Rosen’s research focuses on the development of new cancer therapies, particularly those with novel mechanisms of action. He is the principal investigator of more than 200 phase I clinical trials dating back to 1996, including some of the first involving anti-angiogenesis therapies. Collaborating with research efforts globally, Rosen is most interested in pharmacodynamic markers of safety and efficacy and in establishing new methods for the design and conduct of cancer clinical trials.

Selected Cancer-Related Publications:

Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, Figg WD, Spencer S, Adams BJ, Alvarez D, Seon BK, Theuer CP, Leigh BR, Gordon MS. A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer. Clin Cancer Res. 2012 Sep 1;18(17):4820-9. Epub 2012 Jul 5.

Rosen LS, Puzanov I, Friberg G, Chan E, Hwang YC, Deng H, Gilbert J, Mahalingam D, McCaffery I, Michael SA, Mita AC, Mita MM, Mulay M, Shubhakar P, Zhu M, Sarantopoulos J. Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors. Clin Cancer Res. 2012 Jun 15;18(12):3414-27. Epub 2012 Apr 17.

Rosen LS, Senzer N, Mekhail T, Ganapathi R, Chai F, Savage RE, Waghorne C, Abbadessa G, Schwartz B, Dreicer R. A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clin Cancer Res. 2011 Dec 15;17(24):7754-64. Epub 2011 Oct 5.

Bello CL, Mulay M, Huang X, Patyna S, Dinolfo M, Levine S, Van Vugt A, Toh M, Baum C, Rosen L. Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib. Clin Cancer Res. 2009 Nov 15;15(22):7045-52. Epub 2009 Nov 10.

Rosen LS, Bilchik AJ, Beart RW Jr, Benson AB 3rd, Chang KJ, Compton CC, Grothey A, Haller DG, Ko CY, Lynch PM, Nelson H, Stamos MJ, Turner RR, Willett CG. New approaches to assessing and treating early-stage colon and rectal cancer: summary statement from 2007 Santa Monica Conference. Clin Cancer Res. 2007 Nov 15;13(22 Pt 2):6853s-6s.